He hardly has enough shares to make that worth while at the moment. Additionally, from a career standpoint it would be his last CEO role if he took the role and 2 months later sells off his shares an drives to company into the ground. If he can get the financials to date (which external accounting firms will be doing) and then successfully launch a Phase 2 trial on a drug that was already approved - not only does he stand to make a ton of money but he would then be a CEO that took a company out of bankruptcy and turned them into a viable company. If he gets them uplisted and maybe even launch a product - he can become a MVP biotech CEO. What your saying just doesn't make sense.
News 
Market Data 
Discover 
